Peregrion is a specialized CRO that supports the acceleration and de-risking of drug development programs. We help pharma companies to collect human Mass Balance and Bioavailability data as early as Phase 1/2a, using our advanced Accelerator Mass Spectrometry (AMS) technology. Founded as a spin-off of TNO, a leading research institute, Peregrion builds on 10+ years of AMS innovation. Our mission is to drive faster, safer, and future-oriented clinical development by delivering early human ADME insights. Trusted by multiple top 20 pharmaceutical companies, our technology uses at least 100-fold lower radioactivity and delivers at least 500-fold higher analytical sensitivity than conventional methods. This means ultra-low dosing is sufficient. Studies can be added in Phase 1/2a of clinical development, saving up to 2 years in development time. What this means for your program: Having the data early in development has multiple benefits; for instance, DDI and impairment studies can be designed using human data, animal metabolism and IV toxicity studies can be waived, and studies can be done as an add-on to existing studies (extra cohort). Peregrion is your trusted go-to partner for the following studies: Mass Balance, Metabolite Profiling, Metabolite Identification, Absolute Bioavailability. • Mass Balance: Insight into the absorption, metabolism, and excretion of drugs. • Metabolite Profiling: Identifying and quantifying metabolites to understand the metabolism of a drug. • Metabolite Identification: Elucidating the structure of unknown metabolites to evaluate drug safety and efficacy. • Absolute Bioavailability: Fraction of a dose that reaches the systemic circulation unchanged. Microtracer studies are our core business. We are experts in data analysis and interpretation. Using our experience, we can support decisions on sample profiling, position of radiolabel, dosing and formulation, bioanalytical methods, etc. We work as an extended team member for your team.